⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18807835 | 0.70 | — | — | |
| SCHEMBL16255563 | 0.63 | — | — | |
| SCHEMBL10760430 | 0.60 | — | — | |
| SCHEMBL3469359 | 0.59 | — | — | |
| SCHEMBL8438270 | 0.59 | — | — | |
| SCHEMBL6850234 | 0.56 | — | — | |
| SCHEMBL21500439 | 0.55 | — | — | |
| SCHEMBL443511 | 0.55 | — | — | |
| SCHEMBL6850203 | 0.55 | — | — | |
| SCHEMBL18111364 | 0.55 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100222326-A1 | New Heterocyclic Derivatives Useful For The Treatment of CNS Disorders | UCB PHARMA, S.A. (BE) | 2010-09-02 | — | — | US | claimed |
| US-20070299067-A1 | Quinoline and isoquinoline derivatives as phosphodiesterase 10 inhibitors | AMGEN INC. | 2007-12-27 | — | — | US | claimed |
| EP-3790885-B1 | 1-IMIDAZOTHIADIAZOLO-2H-PYRROL-5-ONE DERIVATIVES | UCB Biopharma SRL (BE) | 2023-04-19 | — | — | EP | disclosed |
| US-11155565-B2 | 2-oxo-1,3-oxazolidinyl imidazothiadiazole derivatives | UCB Biopharma SRL | 2021-10-26 | — | — | US | disclosed |
| EP-3652183-B1 | 2-OXO-1,3-OXAZOLIDINYL IMIDAZOTHIADIAZOLE DERIVATIVES | UCB Biopharma SRL (BE) | 2021-09-08 | — | — | EP | disclosed |
| US-20210107922-A1 | 1-IMIDAZOTHIADIAZOLO-2H-PYRROL-5-ONE DERIVATIVES | UCB BIOPHARMA SRL (SOCIETE A RESPONSABILITE LIMITEE) (BE) | 2021-04-15 | — | — | US | disclosed |
| US-10806717-B2 | Methods and compositions for improving cognitive function | THE JOHNS HOPKINS UNIVERSITY (US) | 2020-10-20 | — | — | US | disclosed |
| US-20200231599-A1 | 2-OXO-1,3-OXAZOLIDINYL IMIDAZOTHIADIAZOLE DERIVATIVES | UCB BIOPHARMA SPRL (BE) | 2020-07-23 | — | — | US | disclosed |
| US-10154988-B2 | Methods and compositions for treating schizophrenia | THE JOHNS HOPKINS UNIVERSITY (US) | 2018-12-18 | — | — | US | disclosed |
| EP-3400934-A1 | LEVETIRACETAM FOR IMPROVING COGNITIVE FUNCTION | The Johns Hopkins University (US) | 2018-11-14 | — | — | EP | disclosed |
| US-20160038463-A1 | METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION | THE JOHNS HOPKINS UNIVERSITY | 2016-02-11 | — | — | US | disclosed |
| EP-2699581-B1 | 2-OXO-1-IMIDAZOLIDINYL IMIDAZOTHIADIAZOLE DERIVATIVES | UCB BIOPHARMA SPRL (BE) | 2015-11-25 | — | — | EP | disclosed |
| US-20150313876-A1 | METHODS AND COMPOSITIONS FOR TREATING SCHIZOPHRENIA | THE JOHNS HOPKINS UNIVERSITY | 2015-11-05 | — | — | US | disclosed |
| US-8957218-B2 | 2-oxo-1-imidazolidinyl imidazothiadiazole derivatives | UCB PHARMA S.A. (BE) | 2015-02-17 | — | — | US | disclosed |
| US-20140206667-A1 | METHODS AND COMPOSITIONS FOR TREATING SCHIZOPHRENIA | THE JOHNS HOPKINS UNIVERSITY | 2014-07-24 | — | — | US | disclosed |
| US-20140148489-A1 | 2-Oxo-1-Imidazolidinyl Imidazothiadiazole Derivatives | UCB PHARMA, S.A. (BE) | 2014-05-29 | — | — | US | disclosed |
| US-20120214859-A1 | METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION | THE JOHNS HOPKINS UNIVERSITY | 2012-08-23 | — | — | US | disclosed |
| US-20110212928-A1 | METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION | THE JOHNS HOPKINS UNIVERSITY (US) | 2011-09-01 | — | — | US | disclosed |
| US-20100222326-A1 | New Heterocyclic Derivatives Useful For The Treatment of CNS Disorders | UCB PHARMA, S.A. (BE) | 2010-09-02 | — | — | US | disclosed |
| US-20070299067-A1 | Quinoline and isoquinoline derivatives as phosphodiesterase 10 inhibitors | AMGEN INC. | 2007-12-27 | — | — | US | disclosed |